Catalyst
Slingshot members are tracking this event:
Bluebird Bio (BLUE) to present interim data from Starbeam Study of Lenti-D for its effectiveness in treating cerebral adrenoleukodystrophy at the American Academy of Neurology (AAN) 2016
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
BLUE |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 20, 2016
Occurred Source:
http://investor.bluebirdbio.com/phoenix.zhtml?c=251820&p=irol-newsArticle&ID=2158667
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Lenti-d, Phase 2/3 Study, Cerebral Adrenoleukodystrophy, Interim Clinical Data, Neurology Conference, Allo-hsct, Hsct